Cencora, Inc.
COR Healthcare Medical Distribution
Cencora, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $321.3 billion, up 9.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS grew 11.3%, free cash flow grew 3,385.3% and total debt rose 42.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years, revenue growth for ten; insiders bought in the last twelve months.
Follow COR
Cencora, Inc. (COR) EBITDA
Cencora, Inc.'s EBITDA for fiscal 2025 was $3.7B, up 12.2% from $3.3B in fiscal 2024. Over the twelve months to 30 June 2026 it was $4.1B. Over the past ten years it has ranged from −$4.4B (fiscal 2020) to $3.7B (fiscal 2025) — the current reading is the highest in ten years. Cencora, Inc. ranks 2nd of 10 Medical Distribution companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $3.7B | 12.23% |
| FY2024 | $3.3B | (0.83%) |
| FY2023 | $3.3B | 7.98% |
| FY2022 | $3.1B | 6.05% |
| FY2021 | $2.9B | — |
| FY2020 | −$4.4B | — |
| FY2019 | $1.6B | (20.07%) |
| FY2018 | $2.0B | 34.89% |
| FY2017 | $1.5B | (22.17%) |
| FY2016 | $1.9B | 182.80% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $1.4B | (0.56%) |
| Mar 2026 | $1.4B | 37.17% |
| Dec 2025 | $1.0B | 262.75% |
| Sep 2025 | $282.5M | (74.93%) |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| MCK McKesson Corporation compare | $7.3B |
| COR Cencora, Inc. | $4.1B |
| CAH Cardinal Health, Inc. compare | $3.6B |
| HSIC Henry Schein, Inc. compare | $1.0B |
| ACH Accendra Health, Inc. compare | $285.4M |
| COSM Cosmos Health Inc. compare | −$16.9M |
| FOCL FocalTherics compare | −$25.3M |
| AHG Akso Health Group Sponsored ADR compare | −$30.3M |
| HKPD Cellyan Biotechnology Co., Ltd compare | — |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on COR
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement